IRVINE, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. today announced that Russell Skibsted, Senior Vice President and Chief Business Officer of Spectrum Pharmaceuticals, is scheduled to present a corporate overview and update on Thursday, October 5, 2006, at 4:30 p.m. Eastern Time at BioContact Quebec 2006 at the Chateau Frontenac hotel in Quebec, Canada.
The BioContact Quebec 2006 is a biopharmaceutical partnership symposium that brings together over 1,200 participants from biopharmaceutical companies to present various sectors and disciplines of their companies. The conference will be held October 4-6, for more information about the conference please refer to the BioContact Quebec Web site at: www.biocontact.qc.ca/english/default.html.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals opportunistically acquires and advances a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum’s expertise lies in identifying undervalued drug candidates with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company’s pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. For more information, please visit our website at www.spectrumpharm.com.
Forward-looking Statements
This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum’s ability to identify, acquire and develop its portfolio of drug candidates, the Company’s promising pipeline and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that past results may not be indicative of future results, the possibility that price and other competitive pressures may make the marketing and sale of our generic drugs not commercially feasible, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of significant revenues, our limited human and financial resources, our limited experience in establishing strategic alliances, our limited marketing experience, our limited experience with the generic drug industry, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company’s reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
Contacts: Rajesh C. Shrotriya, M.D. Russell Skibsted Chairman, CEO and President SVP & Chief Business Officer Spectrum Pharmaceuticals, Inc. Spectrum Pharmaceuticals (949) 743-9295 949-788-6700
Spectrum Pharmaceuticals, Inc.
CONTACT: Rajesh C. Shrotriya, M.D., Chairman, CEO and President,+1-949-743-9295, or Russell Skibsted, SVP & Chief Business Officer,+1-949-788-6700, both of Spectrum Pharmaceuticals, Inc.
Web site: http://www.spectrumpharm.com/
